https://orcid.org/0000-0001-5535-3485
References
- Ghasemi N, Razavi S, Nikzad E. Multiple sclerosis: pathogenesis, symptoms, diagnoses and cell-based therapy. Cell J. 2017;19(1):1–10.
- Vadalà M, Poddighe D, Laurino C, et al. Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon? EPMA J. 2017;8(3):295–311.
- Tafti D, Ehsan M, Xixis KL. Multiple sclerosis. [Updated 2021 Jan 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls; 2021 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499849/
- Mikaeloff Y, Caridade G, Suissa S, et al. Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood. Neurology. 2009;72(10):873–880.
- Terney D, Beniczky S, Barsi P, et al. Multiple sclerosis after hepatitis B vaccination in a 16-year-old patient. Chin Med J (Engl). 2006;119(1):77–79.
- Fourrier A, Bégaud B, Alpérovitch A, et al. Hepatitis B vaccine and first episodes of central nervous system demyelinating disorders: a comparison between reported and expected number of cases. Br J Clin Pharmacol. 2001;51(5):489–490.
- Ascherio A, Zhang SM, Hernán MA, et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med. 2001;344(5):327–332.
- Malhotra HS, Gupta P, Prabhu V, et al. COVID-19 vaccination-associated myelitis. QJM. 2021;hcab069. DOI:https://doi.org/10.1093/qjmed/hcab069
- Román GC, Gracia F, Torres A, et al. Acute Transverse Myelitis (ATM): clinicalReview of 43 patients with COVID-19-associated ATM and 3 post-vaccination ATM serious adverse events with the ChAdOx1 nCoV-19 vaccine (AZD1222). Frontiers. 2021 Mar 8. [cited 2021 Jul 3]. Available from: https://doi.org/10.3389/fimmu.2021.653786/full